The rising application of algae in nutraceuticals & pharmaceutical industries has influenced the market growth in the recent past. The growing use of algae biomass for nutraceuticals purposes is expected to provide an attractive revenue stream for algae producers. Further, the growing industrial application of algae is providing business opportunities to the companies that have further impacted the market growth.

Inhalation anaesthesia refers to chemical compounds that have general anaesthetic properties and are administered to a patient via inhalation. The global Inhalation anaesthesia market is expected to rise with a CAGR of over 3.5% over forecast period of 2019-2026. Anaesthesia as defined by the Food and Drug Administration (FDA, US) refers to reversible state of unconsciousness resulting in lack of pain and muscle relaxation important for performing surgical procedures.

Throat lozenges are medicated tablets that are used for temporary treatment of sour throat, cough and others. The tablets are intended to slowly dissolve in mouth to soothe and lubricate irritated tissues of the throat and to stop coughs. The throat lozenges are available for sale through over the counter sales and generally may be dispensed without a prescription. The global market for throat lozenges is expected to witness a substantial growth growing with a CAGR of over 4% over the forecast period of 2019-2026. Cold and cough are among the most common diseases, an adult approximately 2 to 4 times is effected by cold in a year as per National Prescribing Service (NPS, Australia). High incidences of cold and cough, growing geriatric population along with growing air population act as key drivers for the growth of the market.

Prebiotic refers to a specialized plant fiber that positively nurtures the good bacteria that are present already in the colon of large bowel. Prebiotics occur naturally in foods such as asparagus, garlic, leeks, chicory, Jerusalem artichokes, onions, oats, wheat and soybeans. The global prebiotic ingredients market is expected to have a CAGR of about 10.4% during the forecast period 2019-2026. Prebiotic influences GALT) gut associated lymphoid tissue positively. FOS, mannooligosaccharides and arabinogalactans are therapeutic nutritional content in prebiotics which helps in influencing GALT. These ingredients lead to optimum gut function and also favors the obstruction of the pathogenic organism’s growth and also proliferate the normal bacterial flora.

The global orthobiological products market is expected to grow with a double digit CAGR of 10% during the forecast period. Development is significantly ascribed to the rising incidences of joint and orthopedic dislocations. Rising worldwide geriatric patient base and growing outdoor activities combined with accidents are other important drivers for the business sector. Rising prevalence of osteoporosis, rheumatoid arthritis and obesity needs therapeutic consideration and surgeries by utilizing orthobiological products is another major factor which is anticipated to boost the market growth during the forecast period.

The global apoptosis market is expected to grow at a significant rate during 2016-2022. Apoptosis is natural and highly regulated process of programmed cell death in body which occurs in multicellular organisms and it generates cell fragments which are known as apoptotic bodies. Process of apoptosis protects body against unusual cell division, viral infection and cells with damaged inherent material.

Increasing incidences of acute and chronic wounds and growing prevalence of wound site infections has been injecting the growth in the global hyperbaric oxygen therapy market. Quickly rising patient pool in developing / emerging markets are the key opportunities available in the global market. The growing demand for the hyperbaric oxygen therapy from the emerging market is creating huge opportunity in the global market. The opportunity is majorly influenced with an increase in thepatient’s pool in the region and rising infectious diseases in the emerging countries.

Clinical chemistry is a type of clinical pathology, clinical biochemistry or medical biochemistry and this market is driving by the various factors such as- Increasing number of chronic disorder, growing laboratory automation, increasing reagent rental agreements, increasing generic population and increasing healthcare expenditure. The cases of chronic diseases such diabetes, heart diseases and depression are continuously increasing and it is driving the market. Specially in North America approx 133 million of people are suffering with the chronic diseases in 2014 and it is projected that during the forecast period the number of chronic diseases patients will increase up to 160 million approx.

The increasing prevalence of lifestyle oriented diseases across the globe and growing adoption of protein based drugs is driving the growth of the global autologous stem cell and non-stem cell based therapies market. Various health regulatory bodies are expecting that universities and companies to innovate new therapy treatments, which ensures better, affordable, safer, easy to use, effective and rapid therapy treatment to end users. Autologous stem cell transplantation is safer than the other transplantation procedure with minimal steps in procedure that provides rapid results.

Growing prevalence of lifestyle oriented diseases across the globe and growing adoption of protein based drugs is driving the global protein engineeringmarket. Decrease in cost for drug discoveryhas a huge impact on the growth of global protein engineering market. Protein engineering is a rapidly growing market and had potentials of lucrative growth opportunity due to rising demand for amino acids and engineered proteins across the globe. Growing prevalence of life style oriented diseases such as blood pressure, diabetes, cardiac diseases and other chronic diseases has been expected to increase the demand for engineered proteins across the globe.

The global orphan drugs market is expected to grow at the CAGR of 12.6 % during 2016-2022 and is expected to reach $205700 million till 2022.An orphan drug is a pharmaceutical agent that has being developed specifically to treat a rare disease. There are many factors that drive’s the global orphan drugs market.The major driving factor that drives this market is increase in investment from pharmaceutical companies which are facing loses from other conventional products.

The global alzheimer’s disease therapeutics and diagnostics market is expected to grow at the CAGR of 7.1% during 2015-2022, and it expected to reach $7200 million till 2022.Alzheimer disease is caused due to abnormal working of brain cells, resulting in loss of cognitive functions due to failure of synaptic transmission. There are various symptoms of alzheimer disease like repetitive movement, agitation, insomnia, memory loss, depression, loss of reasoning abilities and so on. Alzheimer’s disease may even leads to death at its severe stage. Alzheimer’s disease is the common form of dementia, According to National Institute of Aging.

The global infectious disease treatment market is expected to grow with an impressiveCAGR of 8.2% during the forecasted period of 2015-2022. The major factors contributing towards the growth ofmarket isescalating incidences of infectious diseases in the global market. HIV is the major health issue across the globe, according to WHO, in 2014 around 34 million people claimed it and around 1.6 million people died dueto HIV globally. However, in 2014 around 9.6 million people sufferedby TB and around 1.5 million people died due to TB during 2014.

The global erythropoietin stimulating agents market is expected to grow at the CAGR of 0.3% during 2015-2022, and it is expected to reach $7.4 billion by 2022. An erythropoiesis stimulating agent is a medicine similar to erythropoietin which stimulates red blood cell production. ESA, structurally and biologically similar to naturally occurring protein erythropoietin. These type of agents are used in conditions where there is reduced blood production in the body which causes anemia such as HIV, cancer, chronic kidney diseases.

The global hematological disorder drugs and diagnostics market is segmented on the basis of product type and end-users. On the basis of different product the market is segmented as analyzers and reagents. Hematology analyzers are used for diagnostics like to count blood cells in a blood sample, erythrocyte sedimentation rates (ESRs) tests etc. These analyzers are typically integrated with automation for presentation of results and processing analysis.

The Global Market and technologies for advanced drug delivery system is expected to grow at the CAGR of 7.6% during 2015-2022.The drivers which helps to increase the market are increasing chronic diseases in human beings, rising biologics market and advancement of drug innovation and technology. The major factors driving the market is increasing chronic diseases in human beings. The chronic disease are a long term despises whose precautions are taken very long. For example heart disease, diabetes, stroke, and chronic respiratory problems

The global biosimilars market is expected to grow at the an CAGR of 22.6% from 2015 to 2022 and expected to reach $6.22billion by 2022.The major factors driving the market are increase in number off patented drugs and growing geriatric population leading to increasing chronic disease incidences.

The global contraceptive market is estimated to grow at 4.3% during 2015-2022 and is estimated to be $32.85 billion by 2022. Increasing prevalence of sexually transmitted diseases and growing need for population control. The global contraceptive market is majorly driven by various factors such as growing prevalence of sexually transmitted infections (STIs), such as HIV. The introduction of new products, exhibiting improved efficacy are expected to drive the contraceptive market over the forecast period.

The global ophthalmic drugs market is expected to grow at a CAGR of 7% during 2015-2022 and is estimated to be approximately $XX billion at the end of the forecasted period i.e. by 2022. The market is driven by various factors which include increase prevalence of eye related disorders such as glaucoma and cataract aging population, regulatory approvals to new drugs and devices, new technologies such as focus on combining drugs and device therapies and increasing economic factors such as rise in disposable income and health expenditure in emerging countries such as India and China.